Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

BIIB092 for Early Alzheimer's Disease (TANGO)

Start: May 3, 2018
End: August 2021
Enrollment: 528

What Is This Study About?

The study will evaluate BIIB092, a monoclonal antibody, in people with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's disease.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 80 Years

Must have:

  • Gradual, progressive change in memory function during more than 6 months
  • MCI due to Alzheimer's disease or mild Alzheimer's disease
  • Objective evidence of cognitive impairment, as shown by Clinical Dementia Rating (CDR) Scale score of 0.5 for MCI or 0.5 or 1 for mild Alzheimer's, Mini-Mental State Examination score of 22-30 (inclusive), and CDR Memory Box score of  0.5
  • Consent to apolipoprotein E (ApoE) genotyping
  • Informant/study partner
  • Beta-amyloid positivity confirmed at screening

Must NOT have:

  • Any medical or neurological/neurodegenerative condition other than Alzheimer's 
  • Clinically significant, unstable psychiatric illness
  • Stroke, mini-stroke, or unexplained loss of consciousness during the past year
  • Brain hemorrhage, bleeding disorder, or cerebrovascular abnormalities
  • History of unstable angina, heart attack, chronic heart failure, or clinically significant conduction abnormalities during the past year
  • Impaired renal or liver function
  • Alcohol or substance abuse during the past year
  • Significant illness or infection during the past year
  • Unstable medication dosing for chronic conditions during the past 4 weeks
  • Unstable medication dosing for Alzheimer's disease during the past 8 weeks
  • Any medication use that may contribute to cognitive impairment or increase risk for adverse events

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.


Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Biogen

Source: ID: NCT03352557

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health